Issue Date: April 1, 2013
Shire To Purchase SARcode Bioscience
Ireland’s Shire will pay $160 million to acquire SARcode Bioscience, a privately owned ophthalmic drug firm based in Brisbane, Calif. The acquisition will give Shire the dry eye disease agent Lifitegrast, which is in Phase III clinical development. The drug is a small-molecule integrin antagonist designed to block a target in the chronic dry eye inflammation cycle. Shire hopes to launch Lifitegrast in the U.S. as early as 2016. Shire . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society